The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

December 7, 2021 • By Jeffrey Curtis, MD, MS, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Research by Charles-Shoeman C, et al.

You Might Also Like
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
Explore This Issue
January 2022

Additional information contextualizing the risk for MACE events was presented from the same trial. Of particular importance to clinicians is to consider the generalizability of the results. More specifically, should clinicians’ concerns for MACE associated with JAK inhibitors apply to their prescribing for all RA patients?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In additional subgroup analyses reported in this abstract, MACE risk with tofacitinib appeared largely confined to higher risk individuals (e.g., age ³65 or those who ever smoked). Event rates in such individuals receiving tofacitinib were 13.1 per 1,000 patient years of exposure, compared with 9.3 per 1,000 patient years, a non-significant 1.41-fold increase (95% CI 0.93, 2.15). In contrast, individuals aged 50–64 and who never smoked were at much lower risk (4.1 per 1,000 patient years), no different than TNF inhibitor-treated patients who had a nearly identical risk, 4.2 per 1,000 patient years, HR 0.98 (95% CI 0.42, 2.31).

These results highlight the importance of patient selection in prescribing JAK inhibitor therapy. Importantly, they suggest that for patients with RA at lower risk for cardiovascular disease (CVD) events, the safety concerns for MACE with JAK inhibitors (rather than TNF inhibitors) may be minimal.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Abstracts 1940 & 19413,4

1940: Malignancies in patients aged ≥50 years with RA and ≥ 1 additional cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors

Research by Curtis J, et al. (Author’s note: I am an author on this abstract.)

1941: The risk of venous thromboembolic events in patients with RA aged ≥ 50 years with ≥ 1 cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors

Research by Charles-Shoeman C, et al.

For cancer, a hazard ratio of 1.48 (95% CI 1.04, 2.09) for all malignancies, excluding non-melanoma skin cancer (NMSC), and 2.02 (95% CI 1.17, 3.50) for NMSC were observed for tofacitinib compared with TNF inhibitors. However, as with the MACE considerations, patient selection remains paramount.

In the subgroup of lower risk individuals (i.e., aged 50 to <65, and never smoked), there was a low rate of malignancy (5.1 per 1,000 patient years) that did not differ from TNF inhibitors (HR 1.16, 95% CI 0.53, 2.55). Event rates for venous thromboembolism (VTE) were likewise low, particularly in those without a history of VTE: 3.1 per 1,000 in patients receiving 5 mg of tofacitinib twice daily. The NNH for VTE was 763 compared with TNF inhibitor therapy.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Research Reviews, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RAIssue: January 2022

You Might Also Like:
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)